Lyle Arnold, Ph.D. | Senior Vice President of Research & Development, Chief Scientific Officer
Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. He has served as Sr. VP of R&D, and CSO at Biocept since 2012. Prior to joining Biocept, Dr. Arnold founded Aegea Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold has served on the board of directors of numerous companies, including Asuragen, as well as, non-profit organizations, and currently serves on the board of Aegea Biotechnologies.
He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences (co-founder), and Gen-Probe (now Hologic). In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 50 issued U.S. patents and more than 160 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Hologic assays that generate more than $500M in product revenue annually. Dr. Arnold is also the inventor of the patented Switch-Blocker technology for detecting extremely rare genetic events that Biocept uses for interrogating ctDNA for cancer associated mutations. In addition, he has authored more than 50 scientific publications.
Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Veena Singh, MD | Senior Vice President and Senior Medical Director
Dr. Singh brings years of laboratory diagnostics experience and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, Dr. Singh led the clinical laboratory team as the Medical Director at the molecular oncology diagnostics company bioTheranostics Inc. Her expertise in validating and launching assays in a CLIA lab setting, along with extensive knowledge of developmental stage biomarkers, serve as a major catalyst for Biocept’s continuing expansion of its offerings.
During Dr. Singh’s tenure at bioTheranostics Inc., the clinical laboratory’s test menu underwent significant expansion to incorporate assays in solid tumor molecular analysis utilizing multiple methodologies and platforms including Next-Generation Sequencing, RT-PCR, IHC and FISH. In addition, she brings a wealth of experience in the fields of regulatory agency compliance and reimbursement (FDA, IVDMIA and Companion Diagnostics).
Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology. She received her medical degree from the University of Transkei in South Africa and is a Fellow of the College of American Pathologists and the American College of Medical Genetics.
Jason C. Poole, Ph.D. | Senior Director, R&D
Dr. Poole specializes in the development of complex molecular diagnostic tests for use in human health and disease using non-invasive methods. Over the last 20 years he has led research and development efforts in the fields of oncology, reproductive biology and infectious disease. His expertise lies in product development using advanced techniques in Next Generation Sequencing, qPCR, and nucleic acid sample preparation. During his most recent role as Director of R&D at Trovagene, Inc. he spear-headed the development of the first Next Generation Sequencing test designed to detect circulating tumor DNA in urine. This and other work led to a number of patents, publications and commercial product releases.
Dr. Poole, began his career with a National Research Service Award from the NIH’s National Institute on Aging. As a Postdoctoral Fellow at UC, Irvine’s Center for Molecular Medicine he designed and developed his first diagnostic test used in the diagnosis of mitochondrial disease.
A graduate of the University of Colorado, Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois School of Medicine in Chicago, IL. His thesis work investigated the role of the tumor suppressor gene p21 and its effects in mediating cellular senescence.
Cecile Rose Vibat, Ph.D. | Senior Director, Clinical and Translational Affairs
Dr. Vibat has over 15 years of biotechnology industry experience with roles in both scientific laboratory research and clinical affairs. Prior to joining Biocept, she was Senior Director of Translational Science and Clinical Affairs at Trovagene where she coordinated the liquid biopsy Clinical Studies programs in oncology and infectious disease. She has also held scientific positions in various molecular diagnostics companies, including Digital Gene Technologies, Neurome, and Sequenom, leading laboratory teams and managing operations of contract genetic analysis services.
Dr. Vibat received her Bachelors degree in Biochemistry from the University of California, Berkeley and her Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign. She is a certified Project Management Professional (PMP).
Tony J. Pircher, Ph.D. | Director of Immunochemistry
Dr. Pircher joined the R&D department at Biocept Inc. in February 2001 and is currently leading the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of predictive and/or prognostic CTC assays. He has extensive experience in developing proteomic and genomic diagnostic assays and is the inventor on several Biocept patents.
He received his Ph.D. in molecular endocrinology from the Karolinska Institute, Stockholm, mentored by Dr. Lars-Arne Haldosen and the world renowned steroid receptor scientist Dr. Jan-Ake Gustafsson. During his postdoctoral training he worked in the field of molecular hematology at the Pennsylvania State University in the highly prolific research lab of Dr. Don M Wojchowski, where he gained extensive experience in the enrichment of erythroid progenitor cells from blood, bone marrow and spleen. He acquired expertise in protein alteration, expression, detection and purification technologies, antibody production and cellular reporter systems.
Pavel Tsinberg | Associate Director, Technology Development
Pavel Tsinberg is one of the original developers of the cell separation device. His multidisciplinary background is useful for integrating engineering, biology, and surface chemistry with clinical assays. Pavel has worked in biotechnology since 1999, focusing on microarrays, prenatal diagnostics, and, finally, CTC detection. He is an inventor or co-inventor on the majority of Biocept’s patents. He is currently involved in developing the next generation of Biocept’s technology platform.
Pavel received a B.S.E in Bioengineering from Columbia University SEAS, and a M.S.E in Biomedical engineering from University of Pennsylvania.